mPRε CRISPR Activation Plasmid (h): sc-408586-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- mPRε CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- mPRε CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by mPRε CRISPR Activation Plasmid (h) and mPRε CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the PAQR9 transcriptional start site. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
mPRε CRISPR Activation Plasmid (h) | sc-408586-ACT | 20 µg | $397.00 |
PAQR9 encodes membrane progesterone receptor epsilon (mPRε), a member of the progestin and adipoQ receptor family implicated in non-classical steroid signaling at the plasma membrane. mPRε has been linked to rapid progesterone-triggered signal transduction that can influence second-messenger pathways, including modulation of cAMP/PKA and MAPK/ERK dynamics, with downstream effects on cell proliferation, differentiation, and stress responses. In human tissues, PAQR9 expression has been observed in hormone-responsive contexts, supporting roles in reproductive biology and broader endocrine regulation. Dysregulated progestin signaling pathways involving PAQR family receptors are relevant to mechanistic studies of hormone-driven phenotypes in cancer biology, metabolic homeostasis, and neuroendocrine function.
mPRε CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous PAQR9 expression without altering the underlying DNA sequence.
mPRε CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the PAQR9 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the PAQR9 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous mPRε expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native PAQR9 locus and enabling the study of mPRε-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of mPRε pathway restoration in tumor cells with silenced or reduced PAQR9 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.